Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Tuberculosis Patients
100%
Indonesia
86%
Pulmonary Tuberculosis
58%
COVID-19
46%
Multidrug-resistant Tuberculosis (MDR-TB)
42%
Jakarta
33%
Type 1 Diabetes Mellitus (T1DM)
30%
Comorbidity
26%
Tuberculosis
24%
Quit Smoking
23%
Tuberculosis Infection
19%
Lung Tuberculosis
19%
Smoking Cessation
19%
Diabetes
18%
Chest X-ray
17%
Quantitative PCR
17%
Brinkman Index
17%
Mycobacterium Tuberculosis (M. tb)
17%
Referral Hospital
16%
CD8 Expression
14%
CD4 Expression
14%
Diagnosis Scheme
14%
Post-tuberculosis
14%
Sputum Culture Conversion
14%
Volatile Organic Compounds (VOCs) Sensor
14%
Exhaled Breath
14%
Asymptomatic Transmission
14%
Antibacterial Susceptibility Patterns
14%
Correlation Expression
14%
Microbacterium
14%
Chronic Pulmonary Aspergillosis
14%
Aspergillus
14%
Clinical Status
14%
Toll-like
14%
CD-8
14%
Body Mass Index
14%
Evidence-based Case Report
14%
Pneumonia Patients
14%
Endotracheal Aspirate
14%
Ventilator
14%
Isolated Bacteria
14%
Iron Intake
14%
TB Patients
14%
Lung Abscess
14%
Clinical Features
14%
Epidemiological Characteristics
14%
Drug Resistance Tuberculosis
14%
Cavity Formation
14%
Omega-6
14%
Smoking Prevalence
14%
Medicine and Dentistry
Lung Tuberculosis
60%
COVID-19
57%
Multidrug Resistant Tuberculosis
42%
Diabetes Mellitus
38%
Nicotine Withdrawal
28%
Comorbidity
26%
Diabetes
21%
Hazard Ratio
19%
Chest Radiograph
19%
Breathing
19%
Drug Resistance
18%
Human Immunodeficiency Virus
17%
Cross Sectional Study
17%
Tuberculosis Treatment
16%
Sputum Culture
15%
Mycobacterium Tuberculosis
15%
Volatile Organic Compound
14%
CD8 Antigen
14%
Culture Conversion
14%
Clinical Feature
14%
Aspergillus
14%
Chronic Pulmonary Aspergillosis
14%
Body Mass Index
14%
Iron Intake
14%
Karnofsky Performance Status
14%
Lung Cavity
14%
Lung Abscess
14%
Adverse Event
14%
Reverse Transcription Polymerase Chain Reaction
14%
Systemic Candidiasis
14%
Patient Referral
14%
Nephrotoxicity
14%
Toll Like Receptor 4
14%
Microbacterium
14%
Cohort Study
14%
Human Immunodeficiency Virus Infection
14%
Cardiorespiratory
14%
Silo-Filler's Disease
14%
Pulmonary Rehabilitation
14%
Telerehabilitation
14%
Tuberculosis
14%
Infection
13%
Severe Acute Respiratory Syndrome Coronavirus 2
12%
Diseases
9%
Group Trial
9%
Dyspnea
9%
Right Lung
9%
Sputum
8%
Smoking Cessation Program
8%
Tuberculostatic Agent
7%
Pharmacology, Toxicology and Pharmaceutical Science
Lung Tuberculosis
60%
Diabetes Mellitus
37%
Comorbidity
35%
Diseases
35%
Multi-Drug-Resistant Tuberculosis
28%
Coronavirinae
28%
Adverse Event
28%
HIV
19%
Cohort Study
18%
Drug Resistance
18%
Mycobacterium Tuberculosis
15%
Microbacterium
14%
RNA Directed DNA Polymerase
14%
Invasive Candidiasis
14%
Lung Cavity
14%
Staphylococcus Aureus
14%
Lung Abscess
14%
Volatile Organic Compound
14%
CD8 Antigen
14%
Nephrotoxicity
14%
Toll Like Receptor 4
14%
Lung Aspergillosis
14%
Clinical Feature
14%
Chronic Obstructive Lung Disease
14%
Group Trial
14%
Aspergillus
14%
Antiinfective Agent
14%
Human Immunodeficiency Virus Infection
14%
Tuberculosis
14%
SARS Coronavirus
14%
Infection
12%
Randomized Controlled Trial
11%
Recurrence Risk
9%
Antibiotics
9%
Cross-Sectional Study
7%
Mortality Rate
7%
Tuberculostatic Agent
7%
Retrospective Study
7%
Gram Positive Bacterium
7%
Carbapenem
5%
Clindamycin
5%